TCG Crossover Management, LLC
CIK 1839948
13F filing for Q2 2026・No. 1,037
- Holdings
- US$4.16B
- Quarter change
- +US$665.14M
- Entries
- 54
- Net bought (estimate)
- +US$82.63M
The quarter change is the holdings' value against the quarter before, price moves included — not what was bought or sold; each institution's page estimates that.
Net bought (estimate)
Each stock's change in shares at the quarter-end price, added up: a new position counts as bought, one sold out as sold, shares held long only. Splits are compared split-adjusted; corporate actions under a new CUSIP are not estimated. An estimate from the filings, not actual trades.
- New 12
- Sold out 7
- Cut 7
- Added 4
- Corporate actions 0
- Unchanged 31
Largest holdings
54 stocks worth US$4.16B, options and bonds left out.
| Stock | This quarter | Shares | Value | Weight |
|---|---|---|---|---|
| ABIVAX SA AMERICAN DEPOSITARY SHARESCOMM | Cut | 6,007,834 | US$800.6M | 19.24% |
| TANGO THERAPEUTICS INCCOMM | Cut | 9,081,201 | US$283.88M | 6.82% |
| CG ONCOLOGY INCCOMM | Unchanged | 3,670,206 | US$260.77M | 6.27% |
| COGTCOGENT BIOSCIENCES INCCOMM | Cut | 4,854,436 | US$187.87M | 4.52% |
| IMMUNOVANT INCCOMM | Unchanged | 4,457,988 | US$171.77M | 4.13% |
| SYRESPYRE THERAPEUTICS INCCOMM | Unchanged | 1,900,582 | US$168.73M | 4.06% |
| DIANTHUS THERAPEUTICS INCCOMM | Unchanged | 1,676,624 | US$163.44M | 3.93% |
| MIRUM PHARMACEUTICALS INCCOMM | Unchanged | 1,062,049 | US$124.33M | 2.99% |
| ZAI LAB LTD-ADRADRS | New | 6,137,627 | US$116.61M | 2.80% |
| AMYLYX PHARMACEUTICALS INCCOMM | Unchanged | 6,243,812 | US$112.14M | 2.70% |
Sign in (free) to see its 50 largest holdings and its trades. Sign in
Filings
The quarter's original 13F filings (SEC).
- 13F-HRFiled August 14, 2026SEC ↗
13F covers long positions in US-listed securities only; the data is SEC's, filed within 45 days of the quarter's end.